Brand rules in.
Consistent outputs out.

Extended PFS in sorafenib-experienced advanced HCC

VANATAR (vanaclostat) demonstrated extended median progression-free survival in patients with advanced hepatocellular carcinoma who had prior sorafenib therapy. In the Phase 3 VANTAGE trial, median PFS was 5.8 months vs 3.9 months with placebo (HR 0.68, p=0.0021). Most common adverse reactions (≥20%) included fatigue, decreased appetite, and nausea. Serious adverse events occurred in 42% of patients. See full Prescribing Information for complete safety profile including warnings and precautions.

#HCC #hepatocellular #carcinoma #oncology

Targeted kinase inhibition in the second-line HCC setting

VANATAR is an oral multi-kinase inhibitor with activity against VEGFR2, FGFR1, and RET pathways implicated in HCC progression. In sorafenib-experienced patients with advanced disease, VANATAR extended median PFS to 5.8 months. Treatment discontinuation due to adverse events occurred in 18% of patients. The most frequent Grade 3-4 adverse reactions included hypertension (12%), fatigue (8%), and thrombocytopenia (7%). Patients should be monitored for hepatotoxicity, bleeding events, and cardiovascular effects.

#precision #oncology #kinase #inhibitor

Evidence-based second-line option after sorafenib progression

For patients with advanced HCC who have progressed on or are intolerant to sorafenib, VANATAR offers an evidence-based option. The VANTAGE trial enrolled 476 patients with Child-Pugh A liver function and ECOG PS 0-1, demonstrating statistically significant PFS benefit. However, VANATAR did not demonstrate overall survival benefit as a primary endpoint (median OS 10.2 vs 9.8 months, p=0.32). Important safety considerations include hepatic impairment monitoring and dose modifications for toxicity management.

#liver #cancer #treatment #sequencing

Understanding the safety profile of VANATAR in pretreated HCC

In the VANTAGE study, VANATAR showed a manageable safety profile in sorafenib-experienced patients with advanced hepatocellular carcinoma, with median PFS of 5.8 months vs 3.9 months (HR 0.68). Treatment-emergent adverse events led to dose reduction in 31% of patients. The most common adverse reactions included fatigue (54%), decreased appetite (38%), nausea (32%), and diarrhea (28%). Contraindications include severe hepatic impairment (Child-Pugh C). Healthcare providers should counsel patients on recognizing signs of liver toxicity and bleeding.

#patient #safety #adverse #event

Positioning VANATAR in the second-line HCC treatment paradigm

The treatment landscape for sorafenib-experienced HCC continues to evolve with multiple therapeutic options. VANATAR demonstrated statistically significant PFS improvement in this population (median 5.8 vs 3.9 months, p=0.0021). Grade 3-4 treatment-emergent adverse events occurred in 61% of VANATAR patients vs 48% in the control arm. Selection among second-line agents should consider individual patient factors including liver function, comorbidities, prior toxicities, and performance status. No direct comparative trials exist between approved second-line HCC therapies.

#treatment #algorithm #HCC #guidelines

Practical guidance for initiating and managing VANATAR therapy

VANATAR is administered orally at 400 mg twice daily in sorafenib-experienced advanced HCC. Dose modifications are recommended for adverse reactions, with reduction to 300 mg twice daily, then 200 mg twice daily as needed. In the VANTAGE trial, this regimen extended median PFS by 1.9 months compared to placebo. Key monitoring includes liver function tests every 2 weeks for the first 8 weeks, then monthly. Permanent discontinuation is required for Grade 4 hepatotoxicity or recurrent Grade 3 despite dose reduction. Drug interactions via CYP3A4 should be evaluated.

#clinical #practice #HCC #treatment

A decade of answers you deserved sooner.

When your loved one's symptoms don't fit the usual patterns, trust your instincts. Adult-onset AADC deficiency can be misdiagnosed for 10+ years, often mistaken for Parkinson's or other movement disorders. Earlier recognition can change the trajectory of care. Learn the distinct signs that set AADC apart: fluctuating motor symptoms, sleep-wake disturbances, and autonomic changes. Important safety information: SYRELIO is investigational and not approved for any use. Potential risks are being evaluated in ongoing clinical studies.

#AADCDeficiency #RareDisease #CaregiverSupport #NeuroHealth

When the diagnosis doesn't explain what you're seeing.

Does your loved one experience motor symptoms that change throughout the day? Adult-onset AADC deficiency affects fewer than 1 in 100,000 people, yet diagnosis often takes a decade. The disease presents with distinctive patterns: motor fluctuations unresponsive to standard Parkinson's medications, temperature regulation issues, and oculogyric crises. If standard treatments aren't working as expected, genetic testing for AADC may provide clarity. SYRELIO is an investigational therapy currently in clinical trials; efficacy and safety have not been established.

#AADCawareness #MovementDisorders #CaregiverEducation #RareNeurological

The answers exist — but diagnosis takes too long.

You've seen multiple neurologists. Tried medications that didn't help. Watched symptoms worsen without explanation. For many families affected by adult-onset AADC deficiency, this journey lasts 10 years or more. The condition is rare, complex, and frequently confused with more common disorders. Recognition begins with awareness: know that AADC deficiency exists, has a specific biochemical signature, and requires specialized genetic testing. SYRELIO is investigational; potential benefits and risks remain under study in clinical trials.

#DiagnosticJourney #AADCdeficiency #Caregivers #NeurologicalDisorders

A rare diagnosis hiding in plain sight.

Adult-onset AADC deficiency remains one of the most under-recognized neurometabolic disorders in clinical practice. Patients are often treated for atypical Parkinson's for years before enzyme testing reveals the true cause. Key differentiators include: poor levodopa response, early autonomic dysfunction, and plasma AADC enzyme activity testing. Earlier identification allows for appropriate genetic counseling, symptom management, and potential eligibility for investigational programs like SYRELIO. Important: SYRELIO is not approved and its safety profile is still being characterized.

#MedEd #AADCdeficiency #Neurology #RareDisease

You know something's different. Trust that instinct.

Caregivers often notice patterns clinicians overlook. If your loved one's motor symptoms fluctuate unpredictably, aren't helped by standard medications, and include episodes of upward eye deviation, these may point toward AADC deficiency rather than Parkinson's disease. The average time to diagnosis is over 10 years — a delay that impacts quality of life and access to emerging research. Advocate for enzyme and genetic testing if symptoms don't align with initial diagnoses. SYRELIO is investigational; no therapeutic claims can be made at this time.

#CaregiverVoice #AADCawareness #RareDisease #PatientAdvocacy

Recognition is the first step toward better care.

Adult-onset AADC deficiency doesn't have to remain invisible. With greater awareness, genetic testing, and specialized metabolic workups, diagnosis times are improving. Patients and families deserve timely answers — not years of trial-and-error with therapies that don't address the underlying enzyme deficiency. Early recognition opens doors to investigational options, including gene therapy programs like SYRELIO. While SYRELIO is not yet approved and benefits remain unproven, participation in research may offer hope. All investigational therapies carry risk; consult your care team for individualized guidance.

#AADCdeficiency #GeneTherapy #ClinicalTrials #RareDisease

Three medications. Still not controlled. There may be another option.

If you're taking three or more blood pressure medications and your readings are still above goal, your doctor may call this resistant hypertension. CARDIOSEN (cardisetan) is an FDA-approved fourth-line option for adults who haven't reached target blood pressure with maximally tolerated doses of other agents. Like all blood pressure medications, CARDIOSEN carries risks including dizziness, electrolyte imbalances, and potential kidney function changes. Talk to your healthcare provider about whether CARDIOSEN may be appropriate for your individual situation.

#ResistantHypertension #BloodPressureAwareness #HeartHealth #CardiovascularCare

You're doing everything right. But your blood pressure isn't responding.

Many people living with resistant hypertension take their medications exactly as prescribed — and still see numbers that won't budge. If that sounds familiar, you're not alone. CARDIOSEN (cardisetan) is designed specifically for patients whose blood pressure remains elevated despite treatment with three or more antihypertensive drugs. As with any medication, side effects may occur, including headache, fatigue, and changes in lab values. Your healthcare team can help determine if adding a fourth-line agent like CARDIOSEN is the right step for you.

#BPControl #PatientEducation #CardiacHealth #HypertensionJourney

Understanding when standard triple therapy may not be enough.

Resistant hypertension is defined as blood pressure that remains uncontrolled on three different classes of medications at optimal doses. For eligible adults aged 50-75 in this situation, CARDIOSEN (cardisetan) offers an FDA-approved fourth-line treatment approach. Important safety information: CARDIOSEN may cause serious side effects including hyperkalemia, renal impairment, and hypotension. Regular monitoring by your healthcare provider is essential. This medication is not suitable for everyone and requires careful patient selection.

#HypertensionTreatment #CardiacCare #BloodPressureManagement #HeartDisease

You've tried three medications. Your blood pressure is still high. What's next?

Managing resistant hypertension means juggling multiple medications, regular monitoring, and the frustration of numbers that stay stubbornly high. You've been diligent. Your care team has adjusted doses and tried different combinations. Now there's CARDIOSEN (cardisetan) — a fourth-line option approved for adults whose blood pressure remains uncontrolled despite three or more medications. Like all treatments, it comes with potential risks including dizziness, elevated potassium levels, and kidney function changes that require monitoring. In this series, we'll explore what resistant hypertension means and how to have informed conversations with your doctor.

A fourth-line option studied specifically in patients like you.

When first-, second-, and third-line blood pressure medications don't achieve control, CARDIOSEN (cardisetan) provides a treatment option specifically studied in patients with resistant hypertension. While individual results vary, clinical trials showed meaningful blood pressure reductions in eligible patients. Potential side effects include electrolyte disturbances, worsening kidney function, and symptomatic low blood pressure. No medication works for everyone, and CARDIOSEN is not appropriate for patients with certain kidney conditions or electrolyte abnormalities. Your doctor will evaluate whether this fourth-line agent fits your unique medical profile.

#ClinicalEvidence #HypertensionResearch #PatientOutcomes #HeartHealth

Ready to ask your doctor about next steps? Here's how to start the conversation.

Living with resistant hypertension means ongoing conversations with your care team about what's working and what isn't. If you're on three medications and still not at goal, ask your doctor whether CARDIOSEN (cardisetan) might be appropriate. Bring your home blood pressure log, current medication list, and recent lab results. Be ready to discuss potential benefits and risks, including side effects like elevated potassium, kidney changes, and low blood pressure episodes. Together, you and your healthcare provider can determine the best path forward for your cardiovascular health.

#PatientAdvocacy #DoctorConversation #BPManagement #HeartHealthJourney

Your cells work hard. Support them intelligently.

As we age, NAD+ levels naturally decline—a key factor in cellular energy production. Vitalis Longevity Cellular Renewal Complex is formulated to support NAD+ pathways through targeted precursors. This dietary supplement is designed to complement a healthy lifestyle, not replace foundational habits like sleep, nutrition, and movement. Individual results vary and supplementation should align with your overall wellness goals.

#cellular #health #NAD #supplementation

Cellular energy doesn't have to decline with age.

Many adults notice shifts in energy and recovery after 40. Vitalis Cellular Renewal Complex supports the body's NAD+ pathways—critical for mitochondrial function and cellular repair. As with any supplement, effects depend on baseline health, lifestyle factors, and individual biology. Not all users will experience noticeable changes. This product is not intended to diagnose, treat, cure, or prevent any disease.

#longevity #supplement #midlife #health

Metabolism starts at the cellular level.

NAD+ is central to hundreds of metabolic processes. Vitalis Longevity uses research-backed precursors to support these pathways naturally. Our formulation is third-party tested for purity. While promising research exists around NAD+ supplementation, individual outcomes vary widely. We recommend consulting a healthcare provider, especially if you have underlying conditions or take prescription medications.

#metabolic #health #NAD #precursors

Longevity isn't one thing. It's a system.

Whether you're training for a marathon or simply want to feel more resilient, cellular health matters. Vitalis Cellular Renewal Complex is designed for adults seeking to support NAD+ production as part of a comprehensive approach to longevity. Supplements work best alongside quality sleep, nutrient-dense food, and regular movement—not as shortcuts. Results, if any, typically emerge over weeks to months.

#active #aging #longevity #lifestyle

NAD+ 101: What you need to know before supplementing.

You asked about NAD+ supplementation—here's what matters. Vitalis Cellular Renewal Complex delivers precursors like NMN and resveratrol to support your body's natural NAD+ synthesis. This doesn't reverse aging or guarantee specific outcomes; it supports normal cellular function. Efficacy depends on dosage consistency, lifestyle context, and individual physiology. As a dietary supplement, it's not FDA-evaluated for disease treatment. Consider it one tool in a broader longevity strategy.

Not all longevity supplements work the same way.

Unlike older antioxidant supplements, NAD+ precursors target cellular energy at the mitochondrial level. Vitalis Cellular Renewal Complex combines synergistic ingredients shown in research to support these pathways more directly than standard multivitamins. That said, no supplement replaces foundational health practices, and individual responses vary. This product has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.

#NAD #vs #antioxidants #longevity